Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study.
暂无分享，去创建一个
R. Salazar | D. Castellano | R. García-Carbonero | I. Matos | J. Capdevila | Á. Teulé | O. Casanovas | J. Barriuso | V. Alonso | A. Custodio | C. Lopez | J. Manzano | E. Dotor | A. Teule